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Abstract
Study Design: Systematic review.
Objectives: The objective of this study was to conduct a systematic review to determine (1) change in function, pain, and quality
of life following structured nonoperative treatment for degenerative cervical myelopathy (DCM); (2) variability of change in
function, pain, and quality of life following different types of structured nonoperative treatment; (3) differences in outcomes
observed between certain subgroups (eg, baseline severity score, duration of symptoms); and (4) negative outcomes and harms
resulting from structured nonoperative treatment.
Methods: A systematic search was conducted in Embase, PubMed, and the Cochrane Collaboration for articles published
between January 1, 1950, and February 9, 2015. Studies were included if they evaluated outcomes following structured non-
operative treatment, including therapeutic exercise, manual therapy, cervical bracing, and/or traction. The quality of each study
was evaluated using the Newcastle-Ottawa Scale, and strength of the overall body of evidence was rated using guidelines outlined
by the Grading of Recommendation Assessment, Development and Evaluation Working Group.
Results:Of the 570 retrieved citations, 8 met inclusion criteria and were summarized in this review. Based on our results, there
is very low evidence to suggest that structured nonoperative treatment for DCM results in either a positive or negative change in
function as evaluated by the Japanese Orthopaedic Association score.
Conclusion: There is a lack of evidence to determine the role of nonoperative treatment in patients with DCM. However, in the
majority of studies, patients did not achieve clinically significant gains in function following structured nonoperative treatment.
Furthermore, 23% to 54% of patients managed nonoperatively subsequently underwent surgical treatment.
Keywords
systematic review, nonoperative treatment, cervical spondylotic myelopathy, degenerative cervical myelopathy
Introduction
Degenerative cervical myelopathy (DCM) is a progressive spine
disease and themost common cause of spinal cord dysfunction in
adults worldwide.1,2 It is caused by age-related alterations to the
spinal axis, including degeneration of the facet joints, interverteb-
ral discs, and/or vertebral bodies; progressive spinal kyphosis;
and ossification, calcification, or hypertrophy of the spinal liga-
ments.3 These anatomical changes narrow the spinal canal and
may result in progressive cord compression, neurological dete-
rioration, and significantly reduced quality of life.
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Early reports on the natural history of this disease have
defined DCM as a relatively “benign” condition in which
patients are often stable for long periods of time following
symptom onset.4,5 However, there is increasing evidence to
suggest that DCM is a progressive disorder and that myelo-
pathic individuals may experience a gradual stepwise decline
in neurological status.6 A recent systematic review of the lit-
erature reported that 20% to 60% of patients with symptomatic
myelopathy deteriorate by at least 1 point on the Japanese
Orthopaedic Association (JOA) score 3 to 6 years after initial
assessment.7 It is therefore important to recognize early signs
of myelopathy and implement appropriate treatment strategies
to minimize pain, disability, and functional impairment.
Surgery is increasingly recommended as the preferred treat-
ment strategy for patients with DCM as decompression not
only effectively halts disease progression, but also results in
significant gains in function and quality of life.8-12 In contrast,
the effectiveness of structured nonoperative treatment in stabi-
lizing or improving symptoms is not well defined. This knowl-
edge gap makes it challenging to determine the appropriate role
of nonoperative treatment in the management of DCM, partic-
ularly in individuals with mild symptoms. As such, the objec-
tive of this study was to conduct a systematic review of the
literature to address 4 clinical questions. In adult patients with
DCM,
1. What is the change in function, pain, and quality of life
following nonoperative treatment?
2. Does this change in function, pain, and quality of life
vary depending on type of nonoperative treatment?
3. Does the change in function, pain, and quality of life
following nonoperative care differ across subgroups
(eg, myelopathy severity or duration of myelopathy
symptoms)?
4. What are the harms of nonoperative care and what is the
percentage of patients who subsequently undergo
surgery?
Materials and Methods
Electronic Literature Search
We conducted a systematic search in Embase, PubMed, and the
Cochrane Collaboration Library for studies published between
January 1, 1950, and February 9, 2015, to identify studies that
reported on outcomes of structured nonoperative treatment in
patients with DCM. “Structured nonoperative treatment” was
defined as any nonsurgical intervention and included therapeu-
tic exercise, manual therapy, bracing, cervical traction, and
others. Our search was limited to human studies published in
English. Reference lists from the articles produced by the
search were reviewed manually to identify additional publica-
tions. For clinical questions 1 through 4, we included studies
that reported change in function, pain, and/or quality of life
following structured nonoperative treatment in adult patients
(18 years of age) with DCM due to spondylosis, herniated
discs, and/or ossification of the posterior longitudinal ligament.
We also included studies that reported the percentage of
patients who ultimately underwent surgery following a period
of structured nonoperative treatment, as well as studies that
stratified patients based on baseline myelopathy severity. For
clinical question 2, we sought to identify studies that compared
the change in function, pain, and quality of life following com-
peting nonoperative interventions.
Studies were excluded if they (1) included patients under 18
years of age or patients with myelopathy due to infection,
malignancy, or acute injury from acute disc herniation, inflam-
matory arthritis, or trauma; (2) only reported outcomes follow-
ing surgical intervention; (3) did not state what type of
structured nonoperative treatment was performed; (4) did not
evaluate outcome using at least one primary outcome measure
(JOA, Nurick, conversion to surgery following nonoperative
treatment); (5) reported on fewer than 10 patients; (6) were
related to animals or cadavers; and/or (7) were strictly biome-
chanical evaluations. Full inclusion and exclusion criteria are
provided in Table 1. Two investigators (AHD, IBA)
Table 1. PICO Table.
Inclusion Exclusion
Patient Clinical questions 1-4:
 Adult patients (18
years) with myelopathy
due to spondylosis,
herniated disc, and/or
ossification of the
posterior longitudinal
ligament.
 Patients <18 years
of age
 Myelopathy due to
infection,
malignancy, acute
injury, inflammatory
arthritis, or trauma
Intervention Clinical questions 1-4:
 Therapeutic exercise
 Manual therapy
 Bracing
 Cervical traction
 Other nonoperative
treatments
 Surgical intervention
Comparison Clinical question 2:
 Competing
nonoperative
intervention
Outcomes Clinical questions 1-4:
 Quality of life (SF-36)
 Disability (NDI)
 Pain (VAS)
 Functional status (JOA,
Nurick)
 Conversion to surgery
Study design Clinical question 2:
 RCT
 Cohort studies
Clinical questions 1, 3, 4:
 Case series
 Case reports
 Literature review
 Narrative review
 Animal studies
 Studies with <10
patients
Abbreviations: SF-36, Short-Form 36; NDI, Neck Disability Index; VAS, Visual
Analog Scale; JOA, Japanese Orthopaedic Association; RCT, randomized con-
trolled trials.
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independently reviewed the full texts of potential articles and
excluded all studies that did not meet the inclusion criteria
(Figure 1). Selection discrepancies were resolved through
discussion.
Data Extraction
The following data was extracted from each included article:
study design; patient characteristics, including mean age, base-
line severity score, and type of DCM; length and rate of follow-
up; type and duration of nonoperative treatment; outcomes
assessed; and associations between nonoperative management
and outcomes (function, pain, quality of life, and/or conversion
to surgery). We attempted to identify studies with overlapping
data to prevent double-counting. In such cases, we selected the
study with the most complete data, largest sample size, and
greatest follow-up period.
Study Quality and Overall Strength of Body of Literature
Each article was appraised for risk of bias by 2 reviewers
(KTP, JRD) using the modified Newcastle-Ottawa Scale
(NOS).13 Strength of the overall body of evidence for each
outcome was determined by guidelines outlined by the
Grading of Recommendation Assessment, Development and
Evaluation (GRADE) Working Group.14,15 Though the
GRADE scale is intended to rate the quality of evidence
of comparative studies, we adapted its principles for this
systematic review to determine the confidence we have in
our conclusions.
The overall body of evidence is considered Low if all stud-
ies are observational. The quality of the body of evidence may
be upgraded or downgraded depending on a number of factors.
Criteria for downgrading 1 or 2 levels include (1) inconsistency
of results, (2) indirectness of evidence, or (3) imprecision of the
effect estimates (eg, wide variance). Alternately, the body of
evidence may be upgraded 1 or 2 levels based on (1) large
magnitude of effect or (2) dose-response gradient.
A quality level of High indicates high confidence that the
true effect lies close to that of the estimate of effect. A Mod-
erate quality level reflects moderate confidence in the effect
estimate; the true effect is likely to be close to the estimate of
the effect, but there is a possibility that it is substantially dif-
ferent. A Low quality level represents limited confidence in the
effect estimate, and that the true effect may be substantially
different from the estimate of the effect.15 Very Low ratings
indicate very little confidence in the effect estimate; the true
effect is likely to be substantially different from the estimate of
effect. This rating may be used if there is no evidence or if it is
not possible to estimate an effect.
Data Analysis
For clinical questions 1, 2, and 3, JOA or modified JOA
(mJOA) scores before and after structured nonoperative treat-
ment were reported and summarized. The minimal clinically
important difference (MCID) for the JOA has not been estab-
lished; however, expert opinion indicates a score change 2.0
points is considered clinically significant.16,17 Furthermore, the
MCID of the mJOA has been estimated to be between 1 and 2
points.18 For clinical question 4, a summary table was used to
identify the proportion of patients that received surgical inter-
vention after a period of structured nonoperative treatment.
Results
Study Selection
Our initial search yielded 570 citations. Following title,
abstract, and full-text review, we identified 8 studies that met
our inclusion criteria for clinical questions 1, 2, and 3 (Figure 1,
Table 2). Five of these studies also addressed clinical question
4 and reported proportions of patients that subsequently under-
went surgical intervention after a period of structured nono-
perative treatment. Of the remaining 562 studies, 541 were
excluded at title and abstract levels as they primarily focused
on surgical intervention and did not appropriately evaluate
outcome following structured nonoperative treatment. After
full-text review, 20 additional studies were excluded for the
following reasons: inappropriate study design (n ¼ 5),
inclusion of patients with trauma or radiculopathy (n ¼ 3),
abstract publication only (n ¼ 2), inappropriate outcome mea-
sures (n ¼ 2), duplicate data (n ¼ 2), surgical treatment only
(n¼ 1), noncervical condition (n¼ 1), non-English publication
(n ¼ 1), and no description of structured nonoperative inter-
vention (n¼ 2). A list of excluded studies and full data abstrac-
tion tables can be found in the Supplemental Material
(available in the online version of the article).
Summary of Studies and Risk of Bias
Types of structured nonoperative treatment varied across stud-
ies and were not well-defined. Treatments included bed rest,
Figure 1. Results of literature search.
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cervical traction, cervical immobilization or bracing, thermal
therapy, physical therapy, and/or nonsteroidal anti-
inflammatory drugs. Outcomes were assessed using a variety
of measures such as the JOA/mJOA, timed 10-meter walking
test, Neck Disability Index, and Activities of Daily Living.
Some studies also reported rates of conversion to surgery fol-
lowing an initial trial of conservative management.
Based on the modified NOS, 6 studies had “moderately low
risk of bias” and 2 had “moderately high risk of bias.” Signif-
icant methodological flaws included high attrition rate (n ¼ 4),
selection bias in choosing source population (n ¼ 1), and small
sample size (n ¼ 3). A detailed critical appraisal of each study
can be found in the Supplemental Material (available in the
online version of the article).
What Is the Change in Function, Pain, and Quality of Life
Following Structured Nonoperative Treatment for DCM?
Assessment of JOA or mJOA Scores. Six studies reported outcomes
of structured nonoperative treatment using change in JOA (n ¼
5) or mJOA (n ¼ 1) scores from baseline to follow-up (Table
3). Sample sizes ranged from 32 to 90 patients, with mean
baseline JOA/mJOA scores ranging from 11.1 to 14.6.
Response to treatment was minimal, with change scores rang-
ing from 0 to 2.3. Only a single study by Matsumoto et al19
reported a mean JOA change score 2.0 points at final follow-
up (mean ¼ 47 months).
Two additional studies evaluated outcomes using the JOA
but did not report change scores. A retrospective cohort study
by Nakamura et al20 evaluated changes in motor function of the
upper and lower extremities following a variety of structured
nonoperative treatments: continuous head-halter traction (n ¼
2), cervical bracing (n ¼ 19), plaster bed immobility (n ¼ 15),
or Crutchfield’s skull traction (n¼ 28). Extremity function was
assessed in 64 patients (74% male, mean age ¼ 54 years) using
a disability scale from 0 (“severe impairment”) to 4 (“no dis-
ability”) based on JOA scores. At final follow-up (mean ¼ 47
months), 27% (15/56) and 26% (16/61) of patients who
received structured nonoperative treatment had “no disability”
in the upper and lower extremities, respectively.
In a second retrospective study, Yoshimatsu et al21 investi-
gated symptomatic changes in 69 patients with DCM who
elected not to undergo surgery immediately following diagno-
sis. Myelopathy severity and functional disability were
assessed at baseline using the JOA. Of the 69 patients, 12
refused treatment, 37 underwent “rigorous” nonoperative care,
and 20 received nonrigorous care. “Rigorous” treatment con-
sisted of 3 to 4 hours of continuous cervical traction per day for
1 to 3 months, combined with immobilization by cervical
orthosis, exercise therapy, drug therapy, and thermal therapy.
A description of nonrigorous intervention was not provided. To
evaluate treatment effects, baseline and posttreatment JOA
scores were compared and patients were classified into 3
groups based on whether they exhibited “improvement,” “no
change,” or “exacerbation of symptoms” at final follow-up
(mean ¼ 29 months). Twenty-six percent (15/57) of the
patients who received structured nonoperative treatment
demonstrated JOA improvements between baseline and
follow-up, whereas only 8% (1/12) of the patients who refused
structured nonoperative care exhibited functional gains. In
addition, a smaller percentage of patients who received struc-
tured nonoperative care experienced “exacerbation of
symptoms” based on the JOA (58%; 33/57) than those who
refused nonoperative treatment (83%; 10/12). However, the
difference in improvement and exacerbation of symptoms
between patients receiving structured nonoperative care and
those refusing treatment was within the limits of chance.
Does the Change in Function, Pain, and Quality of Life
Vary Depending on Treatment Type?
No studies directly compared outcomes between different stra-
tegies of structured nonoperative treatment; however, one
study evaluated outcomes based on different treatment
“intensities.” A retrospective cohort study by Yoshimatsu
et al21 investigated symptomatic changes in 69 patients with
DCM who received either rigorous or nonrigorous nonopera-
tive treatment. Thirty-eight percent (14/37) of patients receiv-
ing rigorous nonoperative treatment reported some
improvement, whereas only 6% (2/32) of patients receiving
nonrigorous nonoperative treatment reported improvement.
Table 3. Change in (Modified) Japanese Orthopaedic Association Score Following Structured Nonoperative Treatment in Patients With DCM.
JOAb
Author N Follow-up (Months) Treatmenta Baseline Posttreatment Difference
Kadanka et al (2002/2011)34,35 32 36, 120 Immobilization 14.6 14.7 0.1
Li et al (2014)23 38 30.7 Mixed 14.4 15.5 1.1
Matsumoto et al (2001)19 27 47 (12-84) Mixed 13.8+ 1.6 16.1+ 0.9 2.3
Fukui et al (1990)22 50 30 Traction 11.1 12.8 1.7
Shimomura et al (2007)24 70 35.6 (10-60) Traction 14.6+ 1.3 14.7+ 2.0 0.1
Kong et al (2013)28 90 40 (36-56) Traction 14.2+ 1.0 14.2+ 1.3 0
Abbreviations: DCM, degenerative cervical myelopathy; JOA, Japanese Orthopaedic Association.
aSee Table 1 for treatment details.
bSeventeen-point JOA used in all studies except Kadanka et al, who used the 18-point modified JOA.
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The proportion of patients who experienced worsening of
symptoms was 49% (18/37) and 78% (25/32), respectively.
Does the Change in Function, Pain, and Quality of Life
With Nonoperative Care Vary According to Subgroups
(ie, Myelopathy Severity or Duration of Symptoms)?
Duration of Symptoms. Three studies evaluated the correlation
between pretreatment duration of symptoms and posttreatment
JOA scores.20,22,23 Fukui et al22 evaluated changes in func-
tional impairment on the JOA score following 2 weeks of cer-
vical traction. Pretreatment JOA scores for 53 patients ranged
from 6 to 15, with a mean of 11.1 points (3 patients refused
structured nonoperative treatment; n ¼ 50). Fifty-six percent
(28/50) of the patients demonstrated JOA improvements fol-
lowing treatment. In patients with a duration of symptoms less
than 3 months, 80% (12/15) improved by at least 1 point on the
JOA; in contrast, only 46% (16/35) of patients with a duration
of symptoms greater than 3 months exhibited a 1 point JOA
improvement (risk ratio ¼ 1.75; 95% confidence interval ¼
1.13-2.72). Nakamura et al20 also evaluated whether duration
of symptoms is predictive of JOA improvements following
structured nonoperative treatment. For patients with a duration
less than 6 months, 30% (3/10) had “no disability” in the upper
extremity and 36% (5/14) had “no disability” in the lower
extremity following treatment. For patients with a symptom
duration >6 months, a slightly smaller percentage of patients
achieved “no disability” in the upper (26%; 12/46) and lower
(23%; 11/47) extremities. Although these differences were not
statistically significant, the authors indicated that early inter-
vention could result in improved treatment effects following
structured nonoperative treatment.
In a retrospective study, Li et al23 reported a significant
correlation between JOA recovery ratios and disease durations
(r ¼ .888, P < .01) for a combined surgical and nonoperative
group. Patients with a shorter duration of symptoms achieved
superior clinical outcomes.
Baseline Severity Score. There were no studies that stratified their
sample based on pretreatment myelopathy severity.
Other Subgroups. A retrospective cohort study by Matsumoto
et al19 evaluated outcomes following structured nonoperative
treatment in patients with myelopathy secondary to cervical
soft disc herniation. This study analyzed data from 27 patients
with moderate myelopathy (mean baseline JOA 13.8) who
underwent cervical bracing, traction, and nonsteroidal anti-
inflammatory drug therapy for 6 months, with a mean
follow-up time of 3.9 years. Sixty-three percent (17/27) of the
patients demonstrated improvement or stability on the JOA at
final follow-up and 59% (10/17) experienced spontaneous
regression of their disc herniation and a reduction in myelo-
pathy symptoms. The authors concluded that structured non-
operative treatment may improve neurological symptoms in
patients with myelopathy secondary to cervical disc herniation.
What Are the Harms of Nonoperative Care and What Is
the Percentage of Patients Who Convert to Surgery?
No studies reported direct harms of structured nonoperative
treatment. Based on 5 studies, the proportion of patients who
underwent surgical intervention following a period of struc-
tured nonoperative treatment ranged from 23% to 54% (mean
follow-up ¼ 27-74 months; Table 4). In patients with baseline
JOA scores 13.0, 23% to 38% of patients ultimately received
surgery. In patients with more severe myelopathy (JOA < 13.0
[11.1]), Fukui et al22 reported a rate of conversion of 54% (27/
50) following a period of structured nonoperative treatment.
Nakamura et al20 did not specify baseline JOA scores, but did
indicate that 30% (19/64) eventually received surgical inter-
vention at a follow-up period ranging from 36 to 129 months.
Evidence Summary
Eight small studies, ranging in size from 27 to 90 patients, eval-
uated outcomes following structured nonoperative treatment in
patients presenting with mostly mild to moderate DCM (mean
baseline mJOA score 12). mJOA or JOA improvement from
baseline was generally below the MCID, with mean change
scores ranging from 0 to 1 in most studies. One subgroup of
patients with DCM from soft disc herniation reported improved
JOA scores in 63% (17/27) of patients at a mean follow-up of 4
years. The proportion of patients receiving surgery following
nonoperative care ranged from 23% to 54% across 5 small stud-
ies. The quality of evidence for these findings is Very Low.
Discussion
There is increasing evidence to support that surgery results in
significant and clinically meaningful improvements in
Table 4. The Proportion of Patients With DCM Who Converted to Surgery Following Structured Nonoperative Treatment.
Author N Follow-up (Months) Treatmenta Baseline JOA n (%)
Matsumoto et al (2001)19 27 47 (12-84) Mixed 13.8+ 1.6 10 (37%)
Fukui et al (1990)22 50 30 Traction 11.1 27 (54%)
Kong et al (2013)28 90 40 (36-56) Traction 14.2+ 1.0 21 (23%)
Nakamura et al (1998)20 64 74 (36-129) Mixed NR 19 (30%)
Yoshimatsu et al (2001)21 57 29 (1-76) Mixed NR 22 (39%)
Abbreviations: DCM, degenerative cervical myelopathy; JOA, Japanese Orthopaedic Association.
aSee Table 1 for treatment details.
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functional status and quality of life in patients with varying
degrees of myelopathy severity.8-12 In contrast, the role of
nonoperative treatment in these patients has not been well
defined. It is therefore the objective of this review to evaluate
change in function, pain, and quality of life following struc-
tured nonoperative treatment in patients with DCM.
Based on our results, nonoperative treatment does not result
in clinically meaningful or statistically significant gains in
function. Across 6 studies, improvements on the JOA/mJOA
ranged from 0 to 2.3. Interestingly, the greatest reported
improvements following nonoperative care was observed
in patients with myelopathy due to soft disc herniation
(Matsumoto, difference 2.3) and dynamic cervical myelopathy
(Fukui, difference 1.7). These etiologies might be expected a
priori to respond better to nonoperative care, since soft disc
herniations may spontaneously regress, and immobilization
may at least temporarily decrease cord irritation if the primary
mechanism of compression is dynamic rather than static. In
contrast, nonoperative treatment was less effective in patients
with DCM due to static spinal cord compression, or etiologies
that do not tend to regress spontaneously over time (Table 3;
difference in mJOA/JOA for these studies was 0 to 1.1).
Therefore, based on the evidence in this review, nonoperative
care may be reserved for patients with milder myelopathy
secondary to soft disc herniations or dynamic stenosis.
This review also reported that 23% to 54% of patients con-
vert to surgery following an initial period of conservative treat-
ment. Given the large variability in estimates, it is important to
determine which patients are at a higher risk of disease pro-
gression. Important predictors of neurological deterioration and
ultimate conversion to surgery include (1) circumferential cord
compression on an axial magnetic resonance image;24 (2) an
“angular-edged” spinal cord, defined as an acute angled or
lateral corner at one or both sides;25 (3) greater range of pre-
operative neck and head motion;26 (4) lower segmental lordotic
angle and greater percentage of vertebral slip;27 and (5) seg-
mental instability and reduced diameter of the cerebrospinal
fluid column.28 For patients who are in these high-risk groups,
surgical intervention should be recommended regardless of
myelopathy severity. This is especially critical given recent
reports that a longer duration of preoperative symptoms is pre-
dictive of a worse surgical outcome.29,30
To better define the role on nonoperative treatment, out-
comes should be separately evaluated in patients with mild,
moderate, and severe myelopathy. In a recent systematic
review of the literature, Rhee et al investigated the comparative
effectiveness and safety of surgery versus nonoperative man-
agement.31 This review reported that there is little evidence to
suggest that nonoperative treatment halts or reverses the pro-
gression of myelopathy and that nonoperative care should not
be the primary treatment modality in patients with moderate to
severe disease. Surgery should be recommended in these
patients without significant delay, as further disease progres-
sion could result in considerable harm, reduced quality of life,
significant functional disability, and decreased responsiveness
to surgery. In addition, Wu et al reported that myelopathic
patients may be at a higher risk of spinal cord injury or central
cord syndrome, both of which are associated with debilitating
neurologic impairment and increased economic burden.32
In contrast, there may be a role for nonoperative manage-
ment in patients with milder and stable myelopathy. In these
cases, patient preferences must be strongly considered as
patients may be reluctant to undergo surgery for mild symp-
toms, especially if they have not deteriorated over time.
Furthermore, factors that influence the risk-benefit ratio of
either operative or nonoperative management must be weighed
when determining the optimal treatment strategy in these
patients; these include age, comorbidities, duration of symp-
toms, and smoking status. Since no studies stratified their sam-
ples based on preoperative severity, we are unable to determine
whether patients with mild myelopathy (mJOA 15) improve
by the MCID on the mJOA/JOA following structured nono-
perative treatment.
The comparative cost-effectiveness of nonoperative strate-
gies and of nonoperative versus surgical management may
also be considered when developing treatment protocols.
Unfortunately, no studies were identified that compared the
cost-effectiveness of various nonoperative strategies. A recent
study by Witiw et al, however, aimed to evaluate the value
(incremental cost-utility) of surgery versus nonoperative
management using data from 171 Canadian patients enrolled
in either the AOSpine North America or International study.33
Aggregate costs, from a hospital payer perspective (ie, costs
incurred during index admission, readmission, or returns to
the emergency department due to a related complication)
were collected for the duration of the 24-month study period.
These were combined with health-related quality of life
(HRQoL) data to create a 2-dimensional vector of cost and
change in quality of life associated with surgical intervention
for each individual patient. This data was incorporated into a
2-arm, Markov State Transition model where these values for
patients undergoing surgery were compared with estimated
counterfactual outcomes of initial nonsurgical management.
Initial costs from the hospital payer perspective for conserva-
tive management were zero and HRQoL outcomes were based
on data available on the natural history of DCM. In their
primary model, the lifetime incremental cost to utility ratio
(ICUR) was determined to be $11 496 per quality adjusted life
year (QALY) gained for surgical intervention. This point esti-
mate falls well within the criteria defined by the World Health
Organization as very cost-effective. Further testing using a
Monte Carlo probabilistic sensitivity analysis revealed that
97.9% of estimates fell within this threshold, suggesting
robustness to variability in the parameter estimates. To sup-
plement this testing, a highly conservative assumption that
individuals undergoing initial nonoperative management
would not experience any neurologic decline over their life-
time was added to the model. In this scenario, the ICUR was
calculated as $20 548/QALY gained with 94.7% of estimates
falling within the World Health Organization threshold; this
finding further supports the cost-effectiveness of surgical
intervention.
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Limitations
Clinicians who treat myelopathic patients may ask the ques-
tion, “Is it reasonable to prescribe an initial trial of nonopera-
tive care for patients with DCM?” This systematic review
reveals significant flaws in the literature and cannot provide
a strong evidence-based answer to this question. The major
limitation in the body of evidence is that “structured nonopera-
tive care” is often poorly defined and consists of a myriad of
treatments, including traction, bracing, massage, exercise, and
drug administration. The variability of treatment modalities
across studies makes it challenging to derive conclusions
regarding the effectiveness and safety of nonoperative care for
DCM. As presented in Table 5, the level of evidence for each
question was deemed “Very Low,” which means we have little
confidence that the estimate of the treatment effect reflects the
true effect.
There are additional limitations in the body of the evidence.
Studies included in this review poorly defined treatment para-
meters. For example, 4 studies reported that drug therapy was
used as a form of structured nonoperative care.19,21,23,34 How-
ever, none of these studies defined the types of drugs, dosing
instructions, or duration of use. Additionally, 3 studies dis-
cussed other forms of treatment including exercise, thermal
therapy, or physical therapy19,21,23 but did not provide further
description of these treatments, whether they overlapped, the
intensity of administration, and how compliant individuals
were. As a result, we are unable to draw concrete conclusions
about the superiority of various nonoperative treatment mod-
alities over other strategies.
Second, although most studies evaluated functional status
using the JOA, one study used the mJOA, a scale developed to
account for cultural differences between Eastern and Western
Table 5. GRADE Summary Table.
Number of Studies (N)
Strength
of
Evidence Conclusions
Clinical Question 1: What is the change in function, pain and quality of life following structured nonoperative treatment?
mJOA/JOA
improvement
4 prospective cohorts22,24,28,34,35 Very Low There were no clinically meaningful or statistically significant
differences between mJOA/JOA scores at baseline and follow-
up following structured nonoperative treatment for DCM.
Evidence was inconsistent across studies: follow-up durations
ranged from 30 to 74.0 months, baseline mJOA/JOA scores
from 11.1 to 14.6 points, and change in scores following
treatment from 0 to 2.3. One study reported improvement in
JOA score in 26% of their patient population.
4 retrospective cohorts19-21,23 (n ¼ 491)
Clinical Question 2: Does the change in function, pain and quality of life depend on type of nonoperative treatment?
% of patients
with JOA
improvement
1 retrospective cohort21 (n ¼ 57) Very Low A single study reported on the proportion of patients who
improved by 1 point on the JOA score following “rigorous”
versus “nonrigorous” structured nonoperative treatment.
Rigorous versus Nonrigorous Treatment:
38% versus 6% reported improvement in symptoms
49% versus 78% experienced worsening of symptoms
Clinical Question 3: Does the change in function, pain and quality of life following nonoperative care differ across subgroups?
Duration of
symptoms:
Very Low Two studies evaluated outcomes based on pretreatment
duration of symptoms
3 vs >3 months 1 prospective cohort22 (n ¼ 50) 3 months: 80%
JOA: 1 point
improvement
>3 months: 46%, P ¼ .033
<6 vs 6 months 1 retrospective cohort20 (n ¼ 61) <6 months: UE: 30%; LE: 36%
UE JOA: any
improvement
6 months: UE: 26%; LE: 23%; P ¼ ns for both UE and LE
LE JOA: any
improvement
Causative
pathology:
Soft disc
herniation
1 retrospective cohort (n ¼ 27)19 Very Low Based on a single study, 63% of patients demonstrated
improvement or stability on the JOA at final follow-up and 59%
experienced spontaneous regression of their disc herniation.JOA score
Clinical Question 4: What are the harms of nonoperative care and what is the percentage of patients who subsequently undergo surgery?
Surgery
following
nonoperative
care
2 prospective cohorts22,28 Very Low Across 5 studies, 23% to 54% of patients ultimately converted to
surgery following an initial trial of structured nonoperative
treatment. Pretreatment severity was mostly mild to
moderate.
3 retrospective cohorts19-21 (n ¼ 288)
Abbreviations: DCM, degenerative cervical myelopathy; JOA, Japanese Orthopaedic Association; mJOA, modified JOA; UE, upper extremity; LE, lower extremity.
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societies.34,35 A recent study by Kato et al16 compared the orig-
inal JOA with the mJOA and determined that, although the 2
scales are highly correlated (Spearman’s r¼ 0.87), it is not ideal
to use them interchangeably. Consequently, the ability to gen-
eralize mJOA data with JOA data is limited. Furthermore, 2
studies used different methods to assess functional status that
could not be fully compared to change in JOA or mJOA scores.
Third, the MCID of the mJOA has been shown to vary
depending on myelopathy severity: 1 in mild patients (mJOA
 15), 2 in moderate patients (mJOA ¼ 12-14), and 3 in severe
patients (mJOA < 12).18 However, the studies included in this
review did not stratify their sample based on preoperative
severity scores. There may be a role for nonoperative treatment
in mild patients (mJOA  15) if they could demonstrate
improvements on the mJOA by 1 or more points.
Finally, there is a wide range of follow-up duration among
the included studies, which makes it difficult to distinguish
between changes from intervention and changes from natural
disease progression.
Conclusion
There is a lack of evidence to concretely define the role of
nonoperative treatment in patients with DCM. However, in the
majority of studies, patients did not achieve clinically signifi-
cant gains in function following structured nonoperative treat-
ment. Furthermore, 23% to 54% of patients initially managed
nonoperatively subsequently underwent surgical treatment.
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